Caradon Therapeutics, Inc.
Caradon Therapeutics, Inc. develops novel disease-modifying peptide-based therapeutics for cardiometabolic diseases in humans and companion animals using proprietary enabling technology to create long-acting formulations.
Funding history
About Caradon Therapeutics, Inc.
How much funding has Caradon Therapeutics, Inc. raised?
Caradon Therapeutics, Inc. has raised $559K in total funding. The most recent round was Pre-Seed.
Where is Caradon Therapeutics, Inc. headquartered?
Caradon Therapeutics, Inc. is headquartered in Encinitas, CA.
What does Caradon Therapeutics, Inc. do?
Caradon Therapeutics, Inc. develops novel disease-modifying peptide-based therapeutics for cardiometabolic diseases in humans and companion animals using proprietary enabling technology to create long-acting formulations.
What problem does Caradon Therapeutics, Inc. solve?
Cardiometabolic diseases in humans and companion animals need better, disease-modifying treatment options.
What's Caradon Therapeutics, Inc.'s solution?
Caradon Therapeutics develops long-acting, disease-modifying peptide-based therapeutics to treat cardiometabolic diseases.
What makes Caradon Therapeutics, Inc. different?
They say they use a proprietary technology to modify peptide agonists specifically to make them long-acting, built on stated extensive experience developing peptide-based biotech therapies.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
